{"organizations": [], "uuid": "7958e09c376737472da0854fc40d280304aac8a6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-abbvie-announces-results-from-phas/brief-abbvie-announces-results-from-phase-2-study-evaluating-rovalpituzumab-tesirine-for-third-line-treatment-of-patients-with-dll3-expressing-relapsed-refractory-small-cell-lung-cancer-idUSFWN1R40SD", "country": "US", "domain_rank": 408, "title": "BRIEF-Abbvie Announces Results From Phase 2 Study Evaluating Rovalpituzumab Tesirine For Third-Line Treatment Of Patients With DLL3-Expressing Relapsed/Refractory Small Cell Lung Cancer", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-22T14:49:00.000+02:00", "replies_count": 0, "uuid": "7958e09c376737472da0854fc40d280304aac8a6"}, "author": "", "url": "https://www.reuters.com/article/brief-abbvie-announces-results-from-phas/brief-abbvie-announces-results-from-phase-2-study-evaluating-rovalpituzumab-tesirine-for-third-line-treatment-of-patients-with-dll3-expressing-relapsed-refractory-small-cell-lung-cancer-idUSFWN1R40SD", "ord_in_thread": 0, "title": "BRIEF-Abbvie Announces Results From Phase 2 Study Evaluating Rovalpituzumab Tesirine For Third-Line Treatment Of Patients With DLL3-Expressing Relapsed/Refractory Small Cell Lung Cancer", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "sclc", "sentiment": "none"}, {"name": "abbvie inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Market News March 22, 2018 / 12:53 PM / Updated 7 minutes ago BRIEF-Abbvie Announces Results From Phase 2 Study Evaluating Rovalpituzumab Tesirine For Third-Line Treatment Of Patients With DLL3-Expressing Relapsed/Refractory Small Cell Lung Cancer Reuters Staff 1 Min Read March 22 (Reuters) - Abbvie Inc: * ABBVIE ANNOUNCES RESULTS FROM PHASE 2 STUDY EVALUATING ROVALPITUZUMAB TESIRINE (ROVA-T) FOR THIRD-LINE TREATMENT OF PATIENTS WITH DLL3-EXPRESSING RELAPSED/REFRACTORY SMALL CELL LUNG CANCER * ABBVIE INC - ‍WILL NOT SEEK ACCELERATED APPROVAL FOR ROVA-T IN THIRD-LINE RELAPSED/REFRACTORY SMALL CELL LUNG CANCER​ * ABBVIE INC - ‍SAFETY DATA IN TRINITY STUDY WERE CONSISTENT WITH PREVIOUSLY REPORTED STUDIES OF ROVA-T​ * ABBVIE INC - ‍ROVA-T DEMONSTRATED SINGLE AGENT RESPONSES IN ADVANCED SCLC PATIENTS​ * ABBVIE INC - ONGOING PHASE 3 STUDIES, MERU AND TAHOE, WILL CONTINUE TO INVESTIGATE ROVA-T IN FIRST- AND SECOND-LINE SCLC Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-22T14:49:00.000+02:00", "crawled": "2018-03-22T15:04:49.017+02:00", "highlightTitle": ""}